BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 31511295)

  • 1. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer.
    Fendler WP; Weber M; Iravani A; Hofman MS; Calais J; Czernin J; Ilhan H; Saad F; Small EJ; Smith MR; Perez PM; Hope TA; Rauscher I; Londhe A; Lopez-Gitlitz A; Cheng S; Maurer T; Herrmann K; Eiber M; Hadaschik B
    Clin Cancer Res; 2019 Dec; 25(24):7448-7454. PubMed ID: 31511295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
    Weber M; Fendler WP; Ravi Kumar AS; Calais J; Czernin J; Ilhan H; Saad F; Kretschmer A; Hekimsoy T; Brookman-May SD; Mundle SD; Small EJ; Smith MR; Perez PM; Hope TA; Herrmann K; Hofman MS; Eiber M; Hadaschik BA
    Eur Urol; 2024 Jun; 85(6):511-516. PubMed ID: 38490855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study.
    Weber M; Kurek C; Barbato F; Eiber M; Maurer T; Nader M; Hadaschik B; Grünwald V; Herrmann K; Wetter A; Fendler WP
    J Nucl Med; 2021 Jan; 62(1):88-91. PubMed ID: 32444377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
    Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
    Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Dietlein F; Mueller P; Kobe C; Endepols H; Hohberg M; Zlatopolskiy BD; Krapf P; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    Mol Imaging Biol; 2021 Apr; 23(2):277-286. PubMed ID: 33006028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.
    Xiang M; Ma TM; Savjani R; Pollom EL; Karnes RJ; Grogan T; Wong JK; Motterle G; Tosoian JJ; Trock BJ; Klein EA; Stish BJ; Dess RT; Spratt DE; Pilar A; Reddy C; Levin-Epstein R; Wedde TB; Lilleby WA; Fiano R; Merrick GS; Stock RG; Demanes DJ; Moran BJ; Huland H; Tran PT; Martin S; Martinez-Monge R; Krauss DJ; Abu-Isa EI; Alam R; Schwen Z; Pisansky TM; Choo CR; Song DY; Greco S; Deville C; McNutt T; DeWeese TL; Ross AE; Ciezki JP; Boutros PC; Nickols NG; Bhat P; Shabsovich D; Juarez JE; Chong N; Kupelian PA; Rettig MB; Zaorsky NG; Berlin A; Tward JD; Davis BJ; Reiter RE; Steinberg ML; Elashoff D; Horwitz EM; Tendulkar RD; Tilki D; Czernin J; Gafita A; Romero T; Calais J; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2138550. PubMed ID: 34902034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study.
    Farolfi A; Hirmas N; Gafita A; Weber M; Barbato F; Wetter A; Mei R; Pianori D; Hadaschik B; Herrmann K; Castellucci P; Fanti S; Eiber M; Fendler WP
    J Nucl Med; 2021 May; 62(5):675-678. PubMed ID: 32917782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Trial of
    Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
    Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
    Özülker T; Özülker F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
    Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
    Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of tumor sink effect: Insights from
    Tuncel M; Telli T; Tuncalı MÇ; Karabulut E
    Ann Nucl Med; 2021 May; 35(5):529-539. PubMed ID: 33586096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
    Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
    Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a nonnegligible effect of maximum standardized uptake value in the staging and management of prostate cancer with 68Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography imaging? A single-center experience.
    Ekmekcioglu O; Yavuzsan AH; Arican P; Kirecci SL
    J Cancer Res Ther; 2021; 17(6):1351-1357. PubMed ID: 34916365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
    Liu C; Zhu Y; Su H; Xu X; Zhang Y; Song S; Wang B; Ye D; Hu S
    Cancer Med; 2020 May; 9(10):3278-3286. PubMed ID: 32163676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
    Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.